Regulus Therapeutics
RGLS
#6949
Rank
โ‚ฌ0.48 B
Marketcap
7,01ย โ‚ฌ
Share price
0.00%
Change (1 day)
387.17%
Change (1 year)

Regulus Therapeutics (RGLS) - Cash on Hand

Cash on Hand as of March 2025 : โ‚ฌ56.14 Million

According to Regulus Therapeutics's latest financial reports the company has โ‚ฌ56.14 Million in cash and cash equivalents.
A companyโ€™s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.

Regulus Therapeutics - Cash on Hand chart (from 2011 to 2025)

Cash on Hand by year

Year Cash on Hand Change
2024-12-31โ‚ฌ72.81 M238.7%
2023-12-31โ‚ฌ21.49 M-41.11%
2022-12-31โ‚ฌ36.5 M-31.53%
2021-12-31โ‚ฌ53.31 M110.96%
2020-12-31โ‚ฌ25.27 M-17.02%
2019-12-31โ‚ฌ30.45 M150.05%
2018-12-31โ‚ฌ12.18 M-75.67%
2017-12-31โ‚ฌ50.06 M-30.81%
2016-12-31โ‚ฌ72.35 M-30.64%
2015-12-31โ‚ฌ0.10 B-20.58%
2014-12-31โ‚ฌ0.13 B59.11%
2013-12-31โ‚ฌ82.55 M11.31%
2012-12-31โ‚ฌ74.16 M152.49%
2011-12-31โ‚ฌ29.37 M

Cash on Hand for similar companies or competitors

Company Cash on Hand differencediff. Country
GlaxoSmithKline
GSK
โ‚ฌ3.81 B 6,699.01%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sanofi
SNY
โ‚ฌ8.97 B 15,889.32%๐Ÿ‡ซ๐Ÿ‡ท France
Biogen
BIIB
โ‚ฌ3.40 B 5,958.62%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
โ‚ฌ7.02 B 12,416.83%๐Ÿ‡ฌ๐Ÿ‡ง UK
Alnylam Pharmaceuticals
ALNY
โ‚ฌ2.34 B 4,068.13%๐Ÿ‡บ๐Ÿ‡ธ USA
Sangamo Therapeutics
SGMO
โ‚ฌ25.43 M-54.69%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
โ‚ฌ14.17 B 25,144.77%๐Ÿ‡บ๐Ÿ‡ธ USA
Dicerna Pharmaceuticals
DRNA
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA